

This brochure was made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents are the responsibility of AVAC and do not necessarily reflect the views of USAID or the United States Government.

As of April 2014

And many other generous individuals from around the world

Emergency Plan for AIDS Relief through the U.S. Agency for International Development ■ The World Bank through its Development Grant Facility ■ Robert Wood Johnson Foundation ■ The Starr Foundation ■ U.K. Department for International Development ■ The U.S. President's Affairs ■ Ministry of Science & Technology, Government of India ■ National Institute of Allergy and Infectious Diseases ■ Norwegian Royal Ministry of Foreign Affairs ■ Ministry of Foreign Affairs and Cooperation, Spain ■ Ministry of Foreign Affairs of Denmark ■ Ministry of Foreign Affairs of the Netherlands ■ Google Inc. ■ Government of Japan ■ The Hearst Foundations ■ Institut Mérioux ■ Irish Aid ■ James B. Pendleton Charitable Trust ■ of New York, Economic Development Corporation ■ Foundation for the National Institutes of Health ■ The Gilead Foundation ■ GlaxoSmithKline ■ The City of New York ■ Bill & Melinda Gates Foundation ■ Bristol-Myers Squibb ■ Broadway Cares/Equity Fights AIDS ■ The City of New York ■ Bill & Melinda Gates Foundation ■ Bristol-Myers Squibb ■ Broadway Cares/Equity Fights AIDS ■ The City



IAVI gratefully acknowledges the generous support provided by the following major donors



This publication is made possible with support from:

Founded in 1995, AVAC is an international, non-profit organization that uses education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of biomedical HIV prevention options as part of a comprehensive response to the pandemic. AVAC is based in the US, and focuses on issues and priorities in countries where prevention research and implementation are ongoing. Specifically, we seek to deliver proven HIV prevention tools for immediate impact; demonstrate and roll out new HIV prevention options; and develop long-term solutions needed to end the epidemic.



HIV Vaccines by the Numbers

Trials, discoveries,
money and more




MAY 2016
avaac.org

HIV Vaccines by the Numbers

Trials, discoveries, money and more

We know that an HIV vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the HIV epidemic. The road ahead is long, but clinical trials — even those with disappointing results — and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the HIV vaccine field.

THE NUMBER OF HIV VACCINE TRIALS UNDERWAY (2016)




VACCINE STRATEGIES IN CLINICAL TRIALS (2016)*

Vaccine Concept	Vaccine Strategy Phase of research (Locations of trials)	Vaccine Concept	Vaccine Strategy Phase of research (Locations of trials)
Pox-Protein	ALVAC/gp120 MF59 adjuvant Phase I/II (South Africa)	Adenovirus	Ad26.Mos.HIV + Ad26, MVA or gp140 boost Phase I/II (Rwanda, South Africa, Thailand, Uganda, USA)
Pox-Protein	ALVAC/AIDSVAX Phase II (Thailand)	Protein	gp140 Phase I (US)
DNA	DNA + IL-12 adjuvant through electroporation + VSV HIV gag vaccine, Phase I (US)	Lipopeptide	LIPO-5 Phase I/II (France)
Pox-Protein	ALVAC/AIDSVAX Phase II (Thailand)	Adenovirus	Recombinant Adenovirus 26 Vector Phase I (US)
DNA + MVA	DNA + MVA Phase I (Switzerland, US)	Adenovirus	Ad35.RSV.FA2 with Ad26.RSV.FA2 boost Phase I (US)
DNA/Protein	DNA/AIDSVAX Phase I (Uganda)	Recombinant Vector	rAAV1-PG9DP Phase I (UK)
Adenovirus	Ad4-mgag and Ad4-EnvC150 Phase I (US)	Replicating Vector	Replicating Ad26 + mosaic insert Phase I (US)

*Select vaccine strategies in ongoing clinical trials. Some strategies studied in more than one ongoing trial. For more concepts visit www.avac.org/pxrd. Source: AVAC Prevention Research & Development Database (PxRD), www.avac.org/pxrd


NUMBER OF BROADLY NEUTRALIZING ANTIBODIES DISCOVERED



Source: Broadly Neutralizing Antibodies Electronic Resource, (bNAber.org)


TIME TO DEVELOP A VACCINE

Duration between discovery of microbiologic cause of selected infectious diseases and development of a vaccine




Source: AVAC AIDS Vaccine Handbook

HIV VACCINE CLINICAL TRIAL PARTICIPANTS BY REGION (2014)




Source: 2013 HIV Vaccines & Microbicides Resource Tracking Working Group

GLOBAL INVESTMENT IN HIV VACCINE R&D (2014)




Source: 2015 HIV Vaccines & Microbicides Resource Tracking Working Group, www.hivresourcetracking.org

NEW HIV INFECTIONS BY REGION (2014)



Source: UNAIDS Fact Sheet 2015

EPIDEMICS SUCCESSFULLY COMBATED WITH VACCINES (CASES 1980 – TODAY)



THE WORLD NEEDS AN AIDS VACCINE

